
Author Guidelines

The *BioProcessing Journal* is a peer-reviewed, quarterly publication that features the latest technological advancements and best practices for the development and production of safe and effective biologics. Since 2002, the journal has been a leading source of industry trends and techniques for process efficiency with its content specifically designed for professionals in process and analytical methods development, manufacturing, quality systems, regulatory affairs, facility design, and contract services.



« Please print this out and use as a checklist while preparing your manuscript »

1. Manuscript Submission Overview

We welcome the submission of original articles in all areas of bioprocessing that are not under consideration for publication by another periodical, and are not already available on the internet. There are occasions where manuscripts containing information that has been presented in other non-competing publications will be considered—but this is done on a case-by-case basis, and only when the original publisher has provided appropriate consent.

Before submitting a manuscript that includes previously published graphs, tables, or images, authors are responsible for obtaining the prior publisher's written permission. Authors must state affiliations with organizations that have a direct, or indirect, financial interest in the editorial content or products that are discussed in the manuscript. Authors are responsible for all statements made in their work.

Journal production takes place year-round. Therefore, you may submit your completed manuscripts at any time you wish, along with a completed **Copyright Transfer** form ([click here](#)). If you have a particular issue in mind, please refer to our **Editorial Calendar** for specific dates and deadlines.

All manuscripts must be electronically submitted as a Microsoft Word (or comparable) file that has been formatted for use on a PC. Please arrange all references at the end of the manuscript, and provide separate (high resolution) files for figures and images along with their associated captions. All abbreviations, symbols, and acronyms should be spelled out the first time they appear in the text unless they are so well known and standardized as to not allow ambiguity (e.g., DNA).

Please designate one individual as the corresponding author for the manuscript, and include complete contact information for this person including name, organizational title, post-graduate degree (PhD, MD, etc.), address, telephone number, fax number, and email address. Please also include the organizational titles and post-graduate degrees for all additional authors.

Submit By Email: Send your manuscript files to the managing editor (editor@bioprocessingjournal.com). It is highly recommended that your messages include the "request delivery" and "request read" receipt options to confirm their arrival. Attachments larger than 2 MB should be zipped.

Submit By Mail or Courier: You can also ship the files on CD or USB memory stick, along with hardcopy printouts to the Managing Editor at the address at the bottom of this page.

2. Manuscript Acceptance

Once your article has been accepted for production, you will be notified and the *BioProcessing Journal's* managing editor will assign a tentative date for publication. However, the actual publication date for each article is determined shortly before printing and may be different from the date initially assigned. We reserve the right to assign any article to the issue in which it will best fit the Journal's content, and to republish any article in whole or in part in any subsequent issues as determined to be appropriate.

3. The Overall Review Process

All accepted manuscripts are subject to peer review and will be edited for clarity, grammar, and conformity to the style established for the *BioProcessing Journal*. If substantial revisions are recommended (as determined by feedback from the editors and peer reviewers), the article's author(s) will be given the opportunity to make appropriate updates.

After layout, the corresponding author will be emailed an article proof (in PDF format) to review for accuracy. The managing editor will incorporate the author's designated corrections/revisions, obtain final approval, and send the completed Journal issue to the printer. Then our webmaster will post it on the Journal website for readers worldwide to view.

4. Manuscript Focus

Here are some recommendations for the particular focus and direction the author(s) might want to consider when planning their manuscript. We encourage the inclusion of photos, images, tables, and figures to enhance and/or substantiate the article's content.

Analysis & QC. Based on cGMP and regulatory standards. (1,800–3,000 words)

Case Study. Collaborations between product and service providers reflecting their combined efforts in furthering method development and product optimization. (1,800–4,200 words)

Conference Exclusive. Manuscripts based on presentations given at ISBioTech meetings. (2400–4,200 words)

Essay. Written from your point of view. (1,000–2,250 words)

Lead-In Article. Offers insights, reviews, and analysis of the bioprocessing industry. (1,800–3,000 words)

Letter to the Editor. Subject to editing by the publisher. Letters that question, criticize, or respond to points in a previously published

article will be sent to the author for a reply, but without divulging the source of the letter. (100–250 words)

Methods & Data. Descriptions of new and improved methods, or new applications of established technologies. (1,200–3,000 words)

Opinion Editorial. Subject to editing by the publisher. Letters that question, criticize, correspond to points in a previously published article will be sent to the author for a reply, but without divulging the source of the letter. (750–1,800 words)

Perspectives. Providing an overview and commentary on a technology or application. (1,000–3,800 words)

Product Development. Detailed study with data. (2,500–4,000 words)

Regulatory. From those who work in a regulatory role. (1,000–3,800 words)

Supplier Technology. Where product and service providers co-present their core technologies. Scientific information is presented in a commercially-balanced form, avoiding the excessive use of trade names and marketing claims. Unsubstantiated benefits and direct comparisons with a competitor's product should be avoided, and will be screened by the editor. (1,800–4,200 words)

Cell Banking. Cell Engineering. Facility. Lab Notes. Protein Expression. Process Development. Production Management. Raw Materials. Single-Use Components. Include hands-on observations and details/data on the processes and protocols followed. (1,000–2,250 words)

5. Article Images

All illustrations, photos, tables, and figures should be submitted as digital files whenever possible. However, high quality prints suitable for scanning are acceptable. Digital submissions should be supplied in JPEG, TIFF, PDF, or EPS formats with a minimum resolution of 300 dpi. PowerPoint files or images embedded in the manuscript file are generally acceptable. Authors will be contacted if improved resolution is required. All figures and tables should have accompanying captions included in the manuscript. Clearly identify each image and include the order it appears in the text.

6. Front Cover Page

The *BioProcessing Journal* is always looking for striking photographs and illustrations to use on the cover. We prefer graphics that pertain to articles featured within an issue, but we encourage the submission of any interesting graphic (with credits and descriptive text) that may make a good cover. Micrographs of cells used in the bioprocess industry are ideal.

7. References

Where used in the manuscript, place the reference numbers in brackets. Then at the end of the article, please list the references in numerical order. References should be in a standard technical paper style. Include names of author(s), article title, publication title, edition or volume, publisher, year or date published, and the page numbers. Please note that unless a reference has been accepted for publication, it must be designated as "unpublished." When referencing personal communications, include the name, affiliation, and date. For papers presented at meetings, provide the title of the presentation, the paper or abstract number, the complete name of the meeting, and the dates and location. Here are examples of appropriate formatting for your reference:

Magazine or Journal Articles:

- [1] Schlaeger EJ. The protein hydrolysate, Primatone RL, is a cost-effective multiple growth promoter of mammalian cell culture in serum-containing and serum-free media and displays anti-apoptosis properties. *J Immunol Methods* 1996; 194: 191–199.
- [2] Zhang Y, Zhou Y, Yu J. Effects of peptone on hybridoma growth and monoclonal antibody production. *Cytotechnology* 1994; 16: 147–150.

US Federal Agency Publications:

- [3] Centers for Disease Control (CDC). US Public Health Service guideline on infectious disease issues in xenotransplantation. *Morbidity and Mortality Weekly Report* (MMWR) Atlanta (GA): CDC; 2001 Aug 24. Vol 50, No. RR15.
- [4] Center for Biologics Evaluation and Research (CBER). Draft guidance for industry: *Source animal, product, preclinical, and clinical issues concerning the use of xenotransplantation products in humans*. Rockville (MD): CBER; 2001 Feb.

International Regulatory Agency Publications:

- [5] International Conference on Harmonization. ICH Topics Q5A – Notes for guidance on quality of biotechnological products: *Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. Step 4 consensus guideline*. 4 March 1997 (CPMP/ICH/295/95).
- [6] *Cell cultures for veterinary vaccines*. European Pharmacopoeia, 4th ed. General chapter 5.2.4; 2002.

Published in the Federal Register:

- [7] Interim definition and elimination of lot-by-lot release for well-characterized therapeutic recombinant DNA-derived and monoclonal antibody biotechnology products. *Federal Register* 1995; 60: 63048.

Information Published By Industry Organizations:

- [8] Pharmaceutical Manufacturers and Research of America (PhRMA). *Biotechnology products in development*. Washington, DC: PhRMA; 2002.
- [9] The Biotechnology Industry Organization (BIO). *Approved biotechnology drugs*. Washington, DC: BIO; 2003 Feb. <www.bio.org>.

Information Published By Companies:

- [10] Milroy D, Auchincloss C. Monoclonal antibodies – on the crest of a wave. In: *Horizons*. London, United Kingdom: Wood Mackenzie; 2003.
- [11] Mallik A, Pinkus G, Sheffer S. Biopharma's capacity crunch. In: *The McKinsey Quarterly 2002 Special Edition: Risk and Resilience*. McKinsey & Company; 2002. p 9–11.


Books in General:

- [12] Sambrook J. *Molecular Cloning: A Laboratory Manual, 2nd ed*. New York: Cold Spring Harbor Laboratory; 1989.

Articles or Chapters in Books:

- [13] Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K. Analysis of proteins. In: *Short Protocols in Molecular Biology, 4th ed*. New York: John Wiley & Sons Inc.; 1999. p 10–44.

Copyright Transfer



In consideration of the Publisher's reviewing, editing, and accepting the material for publication identified below (the "Work"), and for other good and valuable consideration, and on behalf of all authors and the employer, the undersigned author grants, sells, transfers, assigns and otherwise conveys all rights, title and interest in and to the Work to the *BioProcessing Journal*, with the exclusive worldwide right to publish and sell the Work, under its own name and any other imprints or trade names, during the full term of copyright and all renewals thereof, and to copyright the Work in the *BioProcessing Journal's* name or any other name with exclusive worldwide authority to dispose of said rights in all languages.

Except for material in the public domain, or for which permission has been obtained from the copyright owner, the Author warrants that the Work is original, does not contain libelous or otherwise unlawful language, and does not infringe any copyright, or the personal or proprietary right of any person or entity. The Author certifies that each author has participated in the Work in a substantive way and is prepared to take public responsibility for the Work.

The Author reserves the right and license, at no cost, to utilize, copy, and distribute the Work for scholarly or educational purposes, provided that such material is not for profit, that a proper acknowledgment is given to the source, and that the Publisher has been notified in writing of said usage.

In the event that the Publisher decides not to publish the Work, the Author will be given written notification, and all rights in the Work granted hereunder will revert to the Author.

By signing and returning this document, the Author confirms his or her acceptance of the terms of this copyright transfer and the Author Guidelines, which are stated prior hereto and incorporated herein by reference. No manuscript will be processed until the Publisher has received this form, signed by the Author.

Author Name (printed) _____ Author Signature _____

Title and/or Description of the Work _____

_____ Date Signed _____

If the above-referenced Work was written as part of the duties of a US Government employee, an assignment of the copyright cannot be made and the Author must sign the following certification. Do not complete this section if the work was prepared under a government contract or was co-authored by a non-US Government employee.

CERTIFICATION AS A WORK OF THE US GOVERNMENT

This is to certify that ALL authors of the Work are, or were, bona fide officers or employees of the US Government at the time the Work was prepared, and that the Work is a "work for hire" that has been prepared as a part of official duties, and is therefore not subject to US copyright.

Author Name (printed) _____ Author Signature _____

Title and/or Description of the Work _____

_____ Date Signed _____